Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.
Discovery of sensitizing mutations in epidermal growth factor receptor (EGFR)and the subsequent development of EGFR tyrosine kinase inhibitors (TKIs) have substantially changed the treatment of lung cancer. First-line treatment with EGFR TKIs (gefitinib, erlotinib and afatinib) has demonstrated a superior response rate and progression-free survival (PFS) compared with chemotherapy inEGFR-mutation positive patients. However, a number of open questions remain, such as choice between the three EGFR TKIs licensed, treatment of patients unsuitable for chemotherapy due to morbidity or advanced age, management of acquired resistance and optimal biological sample to determineEGFRstatus. Recently the first head-to-head trial comparing gefitinib and afatinib (LUX-Lung 7) has been reported. Moreover, third-generation EGFR TKIs such as osimertinib, rociletinib, olmutinib and ASP8273, with preferential activity against T790M mutant tumours, the commonest resistance mechanism to EGFR TKIs, have shown promising results in early clinical trials, with osimertinib now licensed. In this review, we summarize latest advances in the treatment ofEGFR-mutation positive patients focusing on controversial areas and emerging challenges to optimally treat these patients in the future.
Department of Medical Oncology, University Hospital La Fe, Valencia, Spain.
Oscar
O
Juan
Royal Marsden Hospital, London SW3 6JJ, UK.
Sanjay
S
Popat
EGFR; mutation; non-small cell lung carcinoma; tyrosine kinase inhibitors